FOSTIMON -Follicle-Stimulating Hormone FSH -75 IU / 1 VIAL -1 VIAL

Fostimon is a drug containing urofollitropin, intended for the treatment of infertility in women and men. Urofollitropin is a form of gonadotropin derived from human urine, and it is used to stimulate follicle development in women and spermatogenesis in men.

Mechanism of action

Urofollitropin works by stimulating the growth and development of follicles in women's ovaries. This leads to an increase in estrogen production and ovulation. In men, urofollitropin promotes the development and maturation of spermatozoa.

Indications for use

Fostimon is prescribed for the treatment of infertility caused by the absence or insufficient function of the gonads, in both women and men. Including conditions associated with ovulation failure, for example, polycystic ovary syndrome.

Dosage and timing of administration

The dosage and duration of treatment are determined individually, depending on the body's response to treatment. Usually, treatment is started with low doses, gradually increasing them depending on the response.

Important warnings and indications

The use of Fostimon during pregnancy and lactation is not recommended.

Drinking alcohol can affect the effectiveness of treatment, so it should be avoided.

A balanced diet and a healthy lifestyle are recommended to improve treatment outcomes.

Advantages of use

Fostimon helps many couples overcome the problem of infertility, providing a high chance of pregnancy. The drug is highly effective in stimulating ovulation and spermatogenesis, which makes it an important tool in the treatment of infertility.

What symptoms and diseases are used?

Anovulatory cycle in women, polycystic ovary syndrome, infertility in men associated with impaired spermatogenesis

ATX code: G03GA04 

Pharmacokinetics

After intramuscular or subcutaneous injection, the bioavailability of FSH is about 70-75%. It is known that FSH is excreted in two phases. The elimination half-life in the first phase is 4 hours, the elimination half-life in the second phase is about 70 hours. Therefore, 72 hours after administration, the plasma level of FSH concentration is significantly lower than the initial level. Renal excretion of FSH in its original biological and immunological form is insignificant. Kinetic profile in special clinical situations: it is not known how the pharmacokinetic properties of urofollitropin will change in case of impaired liver and renal function.